{"id":"ipx203-er-cd-ld","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Motor fluctuations"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels in Parkinson's disease, while carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa in the periphery, allowing more drug to reach the central nervous system. The extended-release formulation with controlled delivery (CD) aims to maintain more stable plasma levels and reduce motor fluctuations compared to immediate-release formulations.","oneSentence":"IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:50.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease motor symptoms"}]},"trialDetails":[{"nctId":"NCT06765668","phase":"PHASE4","title":"A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"Impax Laboratories, LLC","startDate":"2025-02-12","conditions":"Parkinson Disease","enrollment":220},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT03007888","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2016-11-14","conditions":"Advanced Parkinson's Disease","enrollment":28},{"nctId":"NCT02271503","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2015-11","conditions":"Parkinson's Disease","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IPX203 ER CD-LD","genericName":"IPX203 ER CD-LD","companyName":"Impax Laboratories, LLC","companyId":"impax-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency. Used for Parkinson's disease motor symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}